to boost late-stage development of novel therapy to treat life-threatening, virus-induced
by the “InnovFin
EU-finance for innovators”
The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type 16 (HPV16).
HPV16 infection can cause cervical, head & neck and anogenital cancers.
These cancers can be severe and life-threatening, with low overall survival
rates of advanced stages. Cervical cancer is the 2nd most common
cancer in women aged 15 to 44 years in Europe, with HPV16 causing over 35,000
new cases and 15,000 deaths each year. The
– Seasoned biotech expert to support corporate development
Leiden, The Netherlands, September 02, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the addition of Dr. Markwin Velders to its Supervisory Board. Dr. Velders brings many years of experience in the biotech industry and currently holds a position as VP Operations and Managing Director at Kite Pharma EU, a leading company in the field of immuno-oncology and cell therapy.
“As we are entering the final stages of clinical development for our lead product ISA101b, we are happy to further
Nice read published on MedPage Today about ISA’s phase 2 trial with our lead product ISA101, led by Bonnie Glisson.
Investigators from the University of Texas MD Anderson Cancer Center assessed the potential synergy between tumor-specific vaccine ISA101 and anti–PD-1 immune checkpoint antibody (nivolumab) in patients with incurable HPV-16–positive cancer.
ecancer interviewed ISA’s Chief Science Officer Prof. Dr. Kees Melief on his views on cancer vaccines during the AACR annual meeting 2019 in Atlanta.
Prof. Melief discusses the favourability of cancer vaccines. Cancer vaccines can be easily applied to large numbers of patients and are low in cost. When combined with chemotherapy and immunotherapy they can have great benefit.
He also speaks about ISA’s latest study looking at the HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer.
In Atlanta Prof. Melief received the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019.
Cornelis J. M. ‘Kees’ Melief, M.D., Ph.D., received the 2019 AACR-CRI Lloyd J. Old Award in Cancer Immunology presented by the American Association for Cancer Research (AACR) and Cancer Research Institute (CRI) during the 2019 AACR Annual Meeting.
Dr. Melief, a member of the CRI Scientific Advisory Council and CLIP Grant Review Committee, is being honored for his work on the development of effective immunotherapies for virus-induced tumors, including a novel vaccine strategy that uses synthetic long peptides (SLP) to target cancers associated with infection by the human papilloma virus (HPV). Arthur N. Brodsky, Ph D. interviewed
– Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Leiden, The Netherlands, March 28, 2019– ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019.
The presentation titled “A strong HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer is associated with prolonged survival”is scheduled for Sunday, March 31, 2019, as part of the session “Predictive Biomarkers for Immunotherapy” (12:45-2:45pm, Marcus Auditorium- Bldg A-GWCC).
– Recognition for outstanding and innovative cancer research
Netherlands, March 19, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology
company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis
Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019
from the American Association of Cancer Research (AACR) and the Cancer Research
Lloyd J. Old Award in Cancer Immunology recognizes an active scientist whose
outstanding and innovative research has had a major impact on the cancer field
and has the potential to stimulate new directions in cancer immunology.
The award was
established in honor of the late Lloyd J. Old, MD, who is
– ISA101b and cemiplimab studied in patients with platinum
refractory HPV16-positive oropharyngeal cancer (OPC)
Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals
B.V., a clinical-stage company dedicated to the development of rationally
designed immunotherapeutics, today announced randomization of the first
patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810).
This double blind, placebo-controlled, randomized,
phase 2 study (NCT03669718) will enroll approximately 164 patients with HPV16-positive oropharyngeal cancer (OPC), who have failed first-line chemotherapy. Patients will be randomly allocated on a 1:1 basis to the combination of cemiplimab/ISA101b or cemiplimab/placebo. In both study arms,
The publication describing the mechanism of improved immunogenicity of conjugation of AMPLIVANT titled “Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication,” by Gijs G. Zom et al. was selected as one of four noteworthy articles in the January edition of the JITC Digest. It reports novel murine data demonstrating the enhanced immunological potency of the novel TLR2-ligand, AMPLIVANT, as an adjuvant in cancer immunotherapy (Zom et al. 2018).
Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology
company, today announced that its Chief Scientific Officer Prof. Cornelis
Melief will give a talk at the upcoming Keystone Cancer Vaccines Conference in
Vancouver, BC, Canada, January 20-24, 2019.
The talk titled
“Therapeutic HPV16 Vaccination Is Effective as Monotherapy in
Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced
Cancers” is scheduled for Thursday, January 24, 2019, at 17:00 as part of the
session “Immune Monitoring of T Cells” (17:00-18-45, Pacific Ballroom).
The data will
outline the T cell response to ISA Pharmaceuticals´ therapeutic vaccine ISA101 and
the resulting clinical activity. ISA101 is directed against the HPV16 oncoproteins